Suppr超能文献

GDF15 通过作用于后脑 AP/NTS 中的 GFRAL 神经元来介导肥胖抵抗。

GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS.

机构信息

St Vincent's Centre for Applied Medical Research, St Vincent's Hospital and University of New South Wales, Sydney, NSW, 2010, Australia.

St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, 2052, Australia.

出版信息

Int J Obes (Lond). 2019 Dec;43(12):2370-2380. doi: 10.1038/s41366-019-0365-5. Epub 2019 May 31.

Abstract

BACKGROUND

Elevated circulating levels of the divergent transforming growth factor-beta (TGFb) family cytokine, growth differentiation factor 15 (GDF15), acting through its CNS receptor, glial-derived neurotrophic factor receptor alpha-like (GFRAL), can cause anorexia and weight loss leading to anorexia/cachexia syndrome of cancer and other diseases. Preclinical studies suggest that administration of drugs based on recombinant GDF15 might be used to treat severe obesity. However, the role of the GDF15-GFRAL pathway in the physiological regulation of body weight and metabolism is unclear. The critical site of action of GFRAL in the CNS has also not been proven beyond doubt. To investigate these two aspects, we have inhibited the actions of GDF15 in mice started on high-fat diet (HFD).

METHODS

The actions of GDF15 were inhibited using two methods: (1) Groups of 8 mice under HFD had their endogenous GDF15 neutralised by monoclonal antibody treatment, (2) Groups of 15 mice received AAV-shRNA to knockdown GFRAL at its hypothesised major sites of action, the hindbrain area postrema (AP) and the nucleus of the solitary tract (NTS). Metabolic measurements were determined during both experiments.

CONCLUSIONS

Treating mice with monoclonal antibody to GDF15 shortly after commencing HFD results in more rapid gain of body weight, adiposity and hepatic lipid deposition than the control groups. This is accompanied by reduced glucose and insulin tolerance and greater expression of pro-inflammatory cytokines in adipose tissue. Localised AP and NTS shRNA-GFRAL knockdown in mice commencing HFD similarly caused an increase in body weight and adiposity. This effect was in proportion to the effectiveness of GFRAL knockdown, indicated by quantitative analysis of hindbrain GFRAL staining. We conclude that the GDF15-GFRAL axis plays an important role in resistance to obesity in HFD-fed mice and that the major site of action of GDF15 in the CNS is GFRAL-expressing neurons in the AP and NTS.

摘要

背景

具有不同功能的转化生长因子-β(TGFb)家族细胞因子生长分化因子 15(GDF15),通过其中枢神经系统受体胶质细胞衍生的神经营养因子受体样(GFRAL),循环水平升高,可导致厌食和体重减轻,从而导致癌症和其他疾病的厌食/恶病质综合征。临床前研究表明,基于重组 GDF15 的药物的给药可能用于治疗严重肥胖。然而,GDF15-GFRAL 途径在体重和代谢的生理调节中的作用尚不清楚。GFRAL 在中枢神经系统中的关键作用部位也尚未得到明确证明。为了研究这两个方面,我们在开始高脂肪饮食(HFD)的小鼠中抑制了 GDF15 的作用。

方法

使用两种方法抑制 GDF15 的作用:(1)8 只处于 HFD 状态的小鼠组通过单克隆抗体治疗中和内源性 GDF15,(2)15 只小鼠组接受 AAV-shRNA 以敲低假设的主要作用部位后脑区孤束核(AP)和孤束核(NTS)中的 GFRAL。在这两个实验中都进行了代谢测量。

结论

在开始 HFD 后不久用 GDF15 单克隆抗体治疗小鼠会导致体重、肥胖和肝脂质沉积比对照组更快增加。这伴随着葡萄糖和胰岛素耐量降低以及脂肪组织中促炎细胞因子表达增加。在开始 HFD 的小鼠中,局部 AP 和 NTS shRNA-GFRAL 敲低同样导致体重和肥胖增加。这种效果与 GFRAL 敲低的有效性成正比,这可以通过定量分析后脑 GFRAL 染色来表示。我们得出结论,GDF15-GFRAL 轴在 HFD 喂养小鼠的肥胖抵抗中起重要作用,并且 GDF15 在中枢神经系统中的主要作用部位是 AP 和 NTS 中表达 GFRAL 的神经元。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验